Mode
Text Size
Log in / Sign up
N/A Completed N=754,745

The Incidence of Venous Thromboembolism in Atopic Dermatitis

Source: ClinicalTrials.gov NCT04969653 ↗
Enrolled (actual)
754,745
Serious AEs
Results posted
Dec 2024
Primary outcomePrimary: Number of Participants With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person. — 2576; 7563 Participants

Summary

This study aims to investigate the incidence of venous thromboembolism in people who are diagnosed with atopic dermatitis.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person.
2576; 7563
SECONDARY
Number of Participants With Diagnosis of Pulmonary Embolism After the Start of Follow-up for Each Person
797; 2942
SECONDARY
Number of Participants With Diagnosis of Deep-vein Thrombosis After the Start of Follow-up for Each Person
1887; 4934
SECONDARY
Number of Male Participants With Diagnosis of Risk of Venous Thromboembolism After the Start of Follow-up for Each Person
1070; 3170
SECONDARY
Number of Female Participants With Diagnosis of Risk of Venous Thromboembolism After the Start of Follow-up for Each Person
1506; 4393
SECONDARY
Number of Participants Aged 18-44 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person
503; 1592
SECONDARY
Number of Participants Aged 45-64 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person
639; 1858
SECONDARY
Number of Participants Aged ≥65 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person
1434; 4113
SECONDARY
Number of Participants BMI <30 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person
1398; 3188
SECONDARY
Number of Participants BMI ≥30 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person
685; 760
SECONDARY
Number of Female Participants Aged 18-44 Using Oestrogen Contraceptive With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person
31; 34
SECONDARY
Number of Participants Having History of an Allergic Condition With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person
193; 203

Eligibility Criteria

Inclusion Criteria

  • All eligible adult people (aged ≥ 18) registered with GP practices contributing data to OPCRD between January 1, 2010 and January 1, 2020, were eligible for inclusion in the study.

Exclusion Criteria

  • People with less than 5 years potential follow up. People with atopic dermatitis that was not active atopic dermatitis during the study period. People without atopic dermatitis but diagnosed with other skin conditions.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04969653). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search